Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis.

Mira JA, Rivero-Juárez A, López-Cortés LF, Girón-González JA, Téllez F, de los Santos-Gil I, Macías J, Merino D, Márquez M, Ríos-Villegas MJ, Gea I, Merchante N, Rivero A, Torres-Cornejo A, Pineda JA; Grupo Andaluz para el Estudio de las Hepatitis Víricas de la Sociedad Andaluza de Enfermedades Infecciosas.

Clin Infect Dis. 2013 Jun;56(11):1646-53. doi: 10.1093/cid/cit103. Epub 2013 Feb 19.

PMID:
23429381
2.

Treatment of Acute Hepatitis C Infection with Pegylated Interferon and Ribavirin in Patients Coinfected with Human Immunodeficiency Virus: A Systematic Review and Meta-Analysis.

Zhang B, Nguyen NH, Yee BE, Yip B, Ayoub WS, Lutchman GA, Nguyen MH.

Intervirology. 2015;58(4):242-9. doi: 10.1159/000437427. Epub 2015 Sep 25. Review.

PMID:
26402746
3.

Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals.

Naggie S, Sulkowski MS.

Gastroenterology. 2012 May;142(6):1324-1334.e3. doi: 10.1053/j.gastro.2012.02.012. Review.

4.

Effect of spleen operation on antiviral treatment in hepatitis C virus-related cirrhotic patients.

Feng B, Zhang W, Luo BF, Song GJ, Wang J, Jin Q, Qin H, Wei L.

World J Gastroenterol. 2014 Nov 7;20(41):15387-97. doi: 10.3748/wjg.v20.i41.15387. Review.

5.

Response to standard of care antiviral treatment in patients with HCV liver cirrhosis - a systematic review.

Bota S, Sporea I, Popescu A, Sirli R, Neghina AM, Danila M, Strain M.

J Gastrointestin Liver Dis. 2011 Sep;20(3):293-8. Review.

6.

Granulocyte colony-stimulating factor for hepatitis C therapy-associated neutropenia: systematic review and economic evaluation.

Tandon P, Doucette K, Fassbender K, Vandermeer B, Durec T, Dryden DM.

J Viral Hepat. 2011 Jul;18(7):e381-93. doi: 10.1111/j.1365-2893.2011.01445.x. Epub 2011 Feb 24. Review.

PMID:
21692951
7.

Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis.

Simmons B, Saleem J, Hill A, Riley RD, Cooke GS.

Clin Infect Dis. 2016 Mar 15;62(6):683-694. doi: 10.1093/cid/civ948. Epub 2016 Jan 19. Review.

8.

Definition and management of anemia in patients infected with hepatitis C virus.

McHutchison JG, Manns MP, Longo DL.

Liver Int. 2006 May;26(4):389-98. Review.

PMID:
16629641
9.

Hepatitis C virus infection in patients with HIV-1: epidemiology, natural history and management.

Kang W, Tong HI, Sun Y, Lu Y.

Expert Rev Gastroenterol Hepatol. 2014 Mar;8(3):247-66. doi: 10.1586/17474124.2014.876357. Epub 2014 Jan 22. Review.

PMID:
24450362
10.

Hepatitis C: epidemiology, diagnosis, natural history and therapy.

Pol S, Vallet-Pichard A, Corouge M, Mallet VO.

Contrib Nephrol. 2012;176:1-9. doi: 10.1159/000332374. Epub 2012 Jan 30. Review.

PMID:
22310776
11.

Is the benefit of treating patients with cirrhosis proven?

Bruno S, Boccaccio V, Russo ML, Maisonneuve P.

Liver Int. 2016 Jan;36 Suppl 1:21-7. doi: 10.1111/liv.13013. Review.

PMID:
26725893
12.

Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection.

Weiler N, Zeuzem S, Welker MW.

World J Gastroenterol. 2016 Nov 7;22(41):9044-9056. Review.

13.

Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis.

Dimova RB, Zeremski M, Jacobson IM, Hagan H, Des Jarlais DC, Talal AH.

Clin Infect Dis. 2013 Mar;56(6):806-16. doi: 10.1093/cid/cis1007. Epub 2012 Dec 7. Review.

14.

Hepatitis C-related liver cirrhosis - strategies for the prevention of hepatic decompensation, hepatocarcinogenesis, and mortality.

Toshikuni N, Arisawa T, Tsutsumi M.

World J Gastroenterol. 2014 Mar 21;20(11):2876-87. doi: 10.3748/wjg.v20.i11.2876. Review.

15.

Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response.

Simmons B, Saleem J, Heath K, Cooke GS, Hill A.

Clin Infect Dis. 2015 Sep 1;61(5):730-40. doi: 10.1093/cid/civ396. Epub 2015 May 17. Review.

16.

Chemoprevention of hepatocellular carcinoma in patients with hepatitis C virus related cirrhosis.

Testino G, Borro P.

World J Hepatol. 2013 Oct 27;5(10):521-7. doi: 10.4254/wjh.v5.i10.521. Review.

17.
18.

Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence.

Nuño Solinís R, Arratibel Ugarte P, Rojo A, Sanchez Gonzalez Y.

Infect Dis Ther. 2016 Dec;5(4):491-508. Epub 2016 Oct 25. Review.

Supplemental Content

Support Center